Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Penpulimab with Chemoradiotherapy for LARC
NCT06853769Phase 1Active, not recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anlotinib and penpulimab in rectal cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathologic Complete Response Rate. Started Sep 2024; status: active, not recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06853769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853769.